IFC Advisory is delighted to be working with Midatech Pharma (LSE AIM: MTPH; NASDAQ: MTP) Midatech is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing a range of improved chemo-therapeutics or new immuno-therapeutics, using its three-proprietary platform drug delivery technologies, all of which are in the clinic.
Client Appointment
Midatech Pharma Appointment
22
Mar
Mar
IFC Office Move
IFC Advisory Limited are pleased to announce that they have moved to new offices in [...]
Sep
Entertainment AI appoints IFC Advisory
Entertainment AI (AIM: EAI), has appointed IFC as its financial public relations and investor relations [...]
Dec
Bould Opportunities appointment
Bould Opportunities (AIM: BOU) have appointed IFC as their financial public relations and investor relations [...]
Nov